Allstate Investment Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Allstate Investment Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$619K	Buy	+5,978	New	+$561K	0.02%	457

Other funds holding BMRN

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Allstate Investment Management's BMRN Position: Q4 2022 in Review

Allstate Investment Management opened a new position in BioMarin Pharmaceuticals (BMRN) in Q4 2022: 5,978 shares worth $619K. The stake represents 0.02% of the portfolio and ranks #457 among its holdings.

579 funds tracked by Wall St. Rank hold BMRN as of Q4 2022.

Allstate Investment Management held 5,978 shares of BioMarin Pharmaceuticals worth $619K as of Q4 2022.
BioMarin Pharmaceuticals was a new Allstate Investment Management position in Q4 2022.
BioMarin Pharmaceuticals made up 0.02% of Allstate Investment Management's portfolio in Q4 2022, its #457 holding.
579 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2022.

Based on Allstate Investment Management's 13F filing for Q4 2022, filed 14 Feb 2023.